ES2548578T3 - Monosebacato de un derivado de pirazol - Google Patents

Monosebacato de un derivado de pirazol Download PDF

Info

Publication number
ES2548578T3
ES2548578T3 ES08867231.6T ES08867231T ES2548578T3 ES 2548578 T3 ES2548578 T3 ES 2548578T3 ES 08867231 T ES08867231 T ES 08867231T ES 2548578 T3 ES2548578 T3 ES 2548578T3
Authority
ES
Spain
Prior art keywords
monosebacato
pyrazole derivative
pyrazole
derivative
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08867231.6T
Other languages
English (en)
Inventor
Hideki Takeuchi
Eiji Tsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2548578T3 publication Critical patent/ES2548578T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto representado mediante la fórmula estructural**Fórmula**

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES08867231.6T 2007-12-27 2008-12-24 Monosebacato de un derivado de pirazol Active ES2548578T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007337985 2007-12-27
JP2007337985 2007-12-27
PCT/JP2008/073405 WO2009084531A1 (ja) 2007-12-27 2008-12-24 ピラゾール誘導体のモノセバシン酸塩

Publications (1)

Publication Number Publication Date
ES2548578T3 true ES2548578T3 (es) 2015-10-19

Family

ID=40824245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08867231.6T Active ES2548578T3 (es) 2007-12-27 2008-12-24 Monosebacato de un derivado de pirazol

Country Status (15)

Country Link
US (1) US8399418B2 (es)
EP (1) EP2228378B1 (es)
JP (1) JP5144683B2 (es)
KR (1) KR101416561B1 (es)
CN (1) CN101910189B (es)
AU (1) AU2008344436B2 (es)
BR (1) BRPI0821773B8 (es)
CA (1) CA2709530C (es)
ES (1) ES2548578T3 (es)
IL (1) IL206576A (es)
MX (1) MX2010007154A (es)
NZ (1) NZ586336A (es)
RU (1) RU2482122C2 (es)
TW (1) TWI426914B (es)
WO (1) WO2009084531A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の１／２フマル酸塩
TW201105338A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
WO2011002012A1 (ja) * 2009-07-01 2011-01-06 大日本住友製薬株式会社 Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬
TW201105336A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Combined medicine of pyrazole derivative and biguanide drug
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9273085B2 (en) 2012-05-07 2016-03-01 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
CN104955481B (zh) 2013-02-04 2017-10-24 大正制药株式会社 便秘症的预防或治疗药
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN112469407B (zh) 2018-03-28 2024-10-01 阿沃林特有限公司 用于治疗餐后低血糖症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287786B6 (sk) * 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
BRPI0313290B1 (pt) * 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CN100413878C (zh) * 2002-08-23 2008-08-27 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
WO2004019958A1 (ja) * 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
JP2007516155A (ja) * 2003-10-14 2007-06-21 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ エストロゲン活性を有する（３ｒ，４ｒ）−トランス−３，４−ジアリールクロマン誘導体
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2006097849A1 (en) * 2005-01-14 2006-09-21 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-carbamoyl and thiocarbamoyl azalides with anti-inflammatory activity
CN101146791B (zh) * 2005-01-21 2013-01-09 阿斯泰克斯治疗有限公司 作为激酶抑制剂的4-(2，6-二氯-苯甲酰基氨基)-1h-吡唑-3-甲酸哌啶-4-基酰胺的酸加成盐
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8343953B2 (en) * 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
UY30082A1 (es) * 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos

Also Published As

Publication number Publication date
TWI426914B (zh) 2014-02-21
AU2008344436B2 (en) 2013-08-29
EP2228378B1 (en) 2015-09-09
JPWO2009084531A1 (ja) 2011-05-19
IL206576A (en) 2014-02-27
CA2709530A1 (en) 2009-07-02
CN101910189B (zh) 2013-06-19
JP5144683B2 (ja) 2013-02-13
IL206576A0 (en) 2010-12-30
US8399418B2 (en) 2013-03-19
TW200934504A (en) 2009-08-16
CA2709530C (en) 2016-02-23
CN101910189A (zh) 2010-12-08
RU2010126230A (ru) 2011-12-27
WO2009084531A1 (ja) 2009-07-09
NZ586336A (en) 2011-06-30
KR101416561B1 (ko) 2014-07-08
AU2008344436A1 (en) 2009-07-09
KR20100102140A (ko) 2010-09-20
BRPI0821773B8 (pt) 2021-05-25
MX2010007154A (es) 2010-10-05
EP2228378A1 (en) 2010-09-15
RU2482122C2 (ru) 2013-05-20
US20100279962A1 (en) 2010-11-04
BRPI0821773A2 (pt) 2015-06-16
EP2228378A4 (en) 2014-05-28
HK1147100A1 (en) 2011-07-29
BRPI0821773B1 (pt) 2020-05-19

Similar Documents

Publication Publication Date Title
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
ES2528026T3 (es) Sales de oxalato de ivabridina cristalino y polimorfos de los mismos
ES2319679T5 (es) Módulo de perforación de cápsulas
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
ES2654395T3 (es) Análogos de amilorida espirocíclicos como bloqueantes de ENaC
ES2525932T3 (es) Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
ES2633317T3 (es) Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
ES2546866T3 (es) Polimorfos de darunavir
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
CY1111671T1 (el) Ετεροκυκλικη ενωση
ES2644750T3 (es) Gaviones
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
ES2448766T9 (es) Profármacos de dolutegravir
CY1112722T1 (el) Μυκητοκτονες συνθεσεις
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
ES2403197T5 (es) Instalación de lavado
ATE541836T1 (de) Polycyclische cinnamid-derivate
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
ES2552324T9 (es) Regulador de caudal
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
ES2390396T7 (es) Procedimiento de preparación de compuestos p-hidroximandélicos eventualmente sustituidos y derivados